Ono Venture Investment Fund 1 takes 11.2% stake in Harness Therapeutics
Published
Ono Venture Investment Fund 1, L.P. has entered the register of Harness Therapeutics, a neurodegenerative therapies firm, with 15,001 Series A1 preferred shares, representing an 11.2% holding. The overall share register expanded materially, suggesting fresh funding. The filing was dated 2 September 2026 and covers the multi-year period from 21 August 2024 to 21 August 2026.
Shareholder data
Source: Companies House confirmation statement (CS01) — period to , filed .
Changes in this confirmation statement
| Type | Shareholder | Shares | Change | Share classes |
|---|---|---|---|---|
| New shareholder | ONO VENTURE INVESTMENT FUND 1, L.P. | 15,001 | — | SERIES A1 PREFERRED 15,001 |
| Increased | DEMENTIA DISCOVERY GENERAL PARTNER LLP, ACTING AS GENERAL PARTNER OF DEMENTIA DISCOVERY GP LP, ACTING AS GENERAL PARTNER OF DEMENTIA DISCOVERY L.P. | 52,698 | +764% | SERIES A1 PREFERRED 33,173 SERIES A2 PREFERRED 13,428 SEED PREFERRED 4,052 ORDINARY 2,045 |
| Increased | TAKEDA VENTURES, INC. | 47,590 | +544% | DEFERRED 40,601 ORDINARY 6,989 |
| Increased | EPIDAREX CAPITAL III UK, LP | 14,538 | +370% | DEFERRED 10,300 ORDINARY 4,238 |
| Increased | DDF PARALLEL LLP | 3,357 | +765% | SERIES A1 PREFERRED 2,112 SERIES A2 PREFERRED 857 SEED PREFERRED 258 ORDINARY 130 |
Current shareholders (5)
| Shareholder | Total shares | Share classes |
|---|---|---|
| DEMENTIA DISCOVERY GENERAL PARTNER LLP, ACTING AS GENERAL PARTNER OF DEMENTIA DISCOVERY GP LP, ACTING AS GENERAL PARTNER OF DEMENTIA DISCOVERY L.P. | 52,698 | ORDINARY 2,045 SEED PREFERRED 4,052 SERIES A1 PREFERRED 33,173 SERIES A2 PREFERRED 13,428 |
| TAKEDA VENTURES, INC. | 47,590 | DEFERRED 40,601 ORDINARY 6,989 |
| ONO VENTURE INVESTMENT FUND 1, L.P. | 15,001 | SERIES A1 PREFERRED 15,001 |
| EPIDAREX CAPITAL III UK, LP | 14,538 | DEFERRED 10,300 ORDINARY 4,238 |
| DDF PARALLEL LLP | 3,357 | ORDINARY 130 SEED PREFERRED 258 SERIES A1 PREFERRED 2,112 SERIES A2 PREFERRED 857 |
Contact the editorial team at editorial@fundingspotter.com